ÂÜÀòÂÒÂ×

Yury Kukushkin is an experienced biotechnology and pharmaceuticals executive currently serving as a Board Observer at Aeovian Pharmaceuticals and an Investment Partner at Hevolution Foundation. Previously, Yury held leadership roles as Managing Director and Investment Director at the JDRF T1D Fund, focusing on equity investments in Type 1 Diabetes innovations. Yury also served as a Board Observer for several companies, including Egle Therapeutics, Inversago Pharma, Code Biotherapeutics, VERALOX Therapeutics, and IM Therapeutics, and was a Venture Partner and Principal at 4BIO Capital, where extensive analysis of public and private biotech companies was conducted. Yury co-founded Future Biotech and possesses a PhD in Biochemistry from both the Max Planck Institute and Ludwig-Maximilians-Universität München, complemented by an Executive Program at Harvard Law School.